DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The Company’s product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg.